# BTK inhibitor + venetoclax, fixed duration

Source: https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/  
OnCo record `btki-plus-venetoclax-fixed-duration` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Block the survival signal and remove the death shield at the same time, for about a year, then stop and stay in remission for years.

## Summary

CAPTIVATE and GLOW (ibrutinib), AMPLIFY (acalabrutinib; FDA approved February 2026), SEQUOIA arm D (zanubrutinib), and CELESTIAL (sonrotoclax + zanubrutinib) all show high uMRD and durable PFS after 12-15 months of therapy. Fixed duration reduces cumulative toxicity and cost versus indefinite BTK inhibition.

## Fields

- Kind: Pairing
- Last checked: 2026-09-07
- Pairs: Acalabrutinib + Venetoclax
- Type: combination
- Rationale: BTK inhibition mobilises CLL cells out of protective lymph-node niches and increases BCL-2 dependence; venetoclax then kills them. The two resistance mechanisms are independent.
- Evidence: Multiple positive phase 3 trials; US approval 2026.

## Sources

- ClinicalTrials.gov NCT03836261: AMPLIFY: https://clinicaltrials.gov/study/NCT03836261
- ClinicalTrials.gov NCT03462719: GLOW: https://clinicaltrials.gov/study/NCT03462719

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Venetoclax](https://onco.cc/drugs/venetoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- trials: [AMPLIFY](https://onco.cc/trials/amplify/), [CAPTIVATE](https://onco.cc/trials/captivate/), [CELESTIAL-TNCLL](https://onco.cc/trials/celestial-tncll/), [GLOW](https://onco.cc/trials/glow/), [SEQUOIA](https://onco.cc/trials/sequoia/)
- key papers: [AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients](https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/)

---
JSON: https://onco.cc/api/v1/entities/btki-plus-venetoclax-fixed-duration.json